Ohiwerei said the company’s turnover for 2015 declined by 15.52 per cent to N8.210 billion from N9.719 billion recorded in 2014, while gross profit stood at N4.351 billion compared with N5.433 billion made in 2014, showing a decline of 19.9 per cent.
However, there was an increase of 5.69 per cent in the net assets to N16.67 billion, from N15.772 billion in 2014.
He, however, promised the shareholders of continuous profitability saying: “The company’s production capacity has tremendously increased and we are optimistic that we would be able to meet the growing need for quality pharmaceutical products in the country.”
He added that the implementation of the Common External Tariff (CET) in Nigeria has equally placed a higher tariff on the importation of raw and packaging materials than on finished good, thus putting local production at the advantage against importation.